US20160067238A1 - Pharmaceutical composition and uses thereof - Google Patents

Pharmaceutical composition and uses thereof Download PDF

Info

Publication number
US20160067238A1
US20160067238A1 US14/787,051 US201414787051A US2016067238A1 US 20160067238 A1 US20160067238 A1 US 20160067238A1 US 201414787051 A US201414787051 A US 201414787051A US 2016067238 A1 US2016067238 A1 US 2016067238A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
myopia
chondrogenesis
atropine
ketorolac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/787,051
Other languages
English (en)
Inventor
Pei-Chang Wu
Chia-Ling Tsai
Chueh-Tan Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaohsiung Chang Gung Memorial Hospital
Original Assignee
Kaohsiung Chang Gung Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaohsiung Chang Gung Memorial Hospital filed Critical Kaohsiung Chang Gung Memorial Hospital
Priority to US14/787,051 priority Critical patent/US20160067238A1/en
Publication of US20160067238A1 publication Critical patent/US20160067238A1/en
Assigned to KAOHSIUNG CHANG GUNG MEMORIAL HOSPITAL, WU, PHILIP reassignment KAOHSIUNG CHANG GUNG MEMORIAL HOSPITAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, Chueh-tan, TSAI, CHIA-LING, WU, PEI-CHANG
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to pharmaceutical compositions and methods for the treating myopia, inhibiting ocular chondrogenic protein, scleral chondrogenesis and inflammation induced chondrogenesis.
  • Myopia is due to progressive elongation of the eye and stretching of the ocular tissues. It is an important public health issue, as it affects approximately 25% of the LS, population, and as high as 80% of the population in some Asian countries. Maculopathy of high myopia has become the leading cause of cataract, glaucoma, retinal detachment, myopic retinal degeneration, visual impairment, and untreatable blindness.
  • Optical and laser surgical corrective techniques have been used to alter the refractive state of the myopic eye. These therapies, however, do not address the abnormal elongation of the eye and thus do not treat pathologic changes of high myopia patients.
  • compositions comprising two anti-chondrogenesis agents are provided herein.
  • the pharmaceutical compositions are effective in treating myopia, reducing one or more chondrogenic proteins and reducing scleral chondrogenesis.
  • Methods for treating myopia comprising administering an effective amount of non-steroidal anti-inflammatory agent (NSAID) to a subject in need thereof to thereby treat myopia are provided.
  • the method for treating myopia further comprises administering an effective amount anti-muscarinic agent.
  • NSAID non-steroidal anti-inflammatory agent
  • Methods for reducing one or more ocular chondrogenic proteins comprising administering an effective amount of one or more anti-chondrogenesis agents to a subject in need thereof to reduce one or more ocular chondrogenic proteins are also provided herein.
  • Methods for reducing scleral chondrogenesis comprising administering an effective amount of one or more anti-chondrogenesis agents to a subject in need thereof to reduce scleral chondrogenesis are also provided herein.
  • Methods for reducing inflammation induced chondrogenesis comprising administering an effective amount of one or more anti-chondrogenesis agents to a subject in need thereof to reduce inflammation induced chondrogenesis in the subject are also provided herein.
  • FIG. 1 illustrates schematically a mechanism for myopia.
  • FIG. 2 is bar graph illustrating the levels of alpha smooth muscle actin ( ⁇ -SMA) and collagen type 2 (Col2) mRNA normalized to ⁇ -actin expression in scleral stem/progenitor cells (SSPCs) with or without Transforming growth factor beta (TGF- ⁇ ) treatment. Data are expressed as fold change over the control sample as determined by the delta-delta Ct method. Bars, SD. * represents statistically significant.
  • ⁇ -SMA alpha smooth muscle actin
  • Col2 collagen type 2
  • TGF- ⁇ Transforming growth factor beta
  • FIG. 3 is an assembly of images illustrating the expression of ⁇ -SMA and Col2 in the sclera of mice with form-deprivation myopia (FDM).
  • Panel A is a photograph of a western blot showing the scleral Col2 and ⁇ -SMA expression levels were increased in FDM eyes.
  • Panel B is a bar graph of densitometry analysis showing the levels of scleral Col2 and scleral ⁇ -SMA in FDM eyes are significantly higher than that of the control eyes.
  • FIG. 4 is a bar graph showing the levels of TGF- ⁇ 1, TGF- ⁇ 2 and TGF- ⁇ 3 mRNA expression in the RPE-choroid complex of the FDM eyes were significantly higher than that of the control eyes.
  • FIG. 5A (a western blot analysis) and FIG. 5B (a bar graph) illustrate the expression profiles of Col2 and ⁇ -SMA in human SSPC treated with 10 ng/ml TGF- ⁇ 2, with or without Atropine, Ketorolac and Diclofenac.
  • FIG. 6 is a bar graph illustrating the myopia progression rate (Diopter per year) in 11 myopia subjects treated with atropine eye drops and the combined atropine and ketolorac eye drops.
  • FIG. 7 is a bar graph illustrating the myopia progression rate of a myopia subject without any treatment, followed by 3 months of ketorolac treatment.
  • FIG. 8A is a bar graph illustrating the level of interleukin 6 (IL-6) mRNA normalized to GADPH expression in the choroids of form deprivation myopia (FDM) mice is higher than that of control mice.
  • FIG. 8B is a bar graph illustrating the level of tumor necrosis factor-alpha (TNF- ⁇ ) in the choroids is higher in the FDM mice than that of control mice. TNF- ⁇ expression is suppressed by ketorolac eye drop.
  • IL-6 interleukin 6
  • TNF- ⁇ tumor necrosis factor-alpha
  • FIG. 9A is a bar graph illustrating the suppressive effect of atropine (A), ketorolac (X1) and a pharmaceutical composition comprising atropine and ketorolac on ⁇ -SMA expression in SSPC in the presence of TGF- ⁇ 2 (T2).
  • the pharmaceutical composition comprising atropine and ketorolac has a synergistic effect on ⁇ -SMA suppression.
  • FIG. 9B is a bar graph illustrating the suppressive effect of atropine (A), ketorolac (X1) and a pharmaceutical composition comprising atropine and ketorolac on Col2 expression in SSPC in the presence of TGF- ⁇ 2 (T2).
  • the pharmaceutical composition comprising atropine and ketorolac has a synergistic effect on Col2 suppression.
  • an “effective amount,” as used herein, includes a dose of an anti-chondrogenesis agent that is sufficient to treat or ameliorate at least one symptom of myopia, or to reduce one or more ocular chondrogenic proteins, scleral chondrogenesis or inflammation induced chondrogenesis.
  • treating refers to palliative uses or results, and/or slowing or inhibiting the advancement of myopia progression and/or myopia shift index.
  • reducing includes slowing the formation of ocular chondrogenic protein, scleral chondrogenesis, inflammation induced chondrogenesis or myopia progression, or myopia shift, or disassembling the ocular chondrogenic proteins that have already been formed.
  • Pharmaceutically acceptable salts of the therapeutic agent of the invention include salts derived from an appropriate base, such as an alkali metal (for example, sodium, and potassium), an alkaline earth metal (for example, calcium, and magnesium), ammonium and NX 4 + (wherein X is C 1 -C 4 alkyl).
  • an alkali metal for example, sodium, and potassium
  • an alkaline earth metal for example, calcium, and magnesium
  • ammonium and NX 4 + (wherein X is C 1 -C 4 alkyl).
  • salts of an amino group include salts of organic carboxylic acids, such as tartaric, aliphatic, cycloaliphatic, aromatic, heterocyclic, carboxylic and sulfonic classes of organic acids, such as, for example, formic, glucuronic, malic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic, algenic, hydroxybutyric, cyclochexylaminosulfonic, galactaric and galacturonic acid and the like, lactobionic, fumaric, and succinic acids; organic sulf
  • salts of a compound having a hydroxy group consist of the anion of said compound in combination with a suitable cation such as Na + , NH 4 + or NX 4 + (wherein X is, for example, a C 1 -C 4 alkyl group), Ca ++ , Li + , Mg ++ , or, K + and zinc or organic salts made from primary, secondary and tertiary amines, cyclic amines, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine and the like. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound in free form.
  • a suitable cation such as Na + , NH 4 + or NX 4 + (wherein X is, for example, a C 1 -C 4 alkyl group), Ca ++ ,
  • myopia refers to a condition associated with a refractive error of one or more eyes, wherein light rays entering the eye to focus in front of the retina rather than directly on the retina.
  • myopia as used herein, encompasses a variety of levels (mild myopia, from 0 to ⁇ 3 diopters; moderate myopia, from ⁇ 3 to ⁇ 5 diopters; and high myopia, from ⁇ 5 or lower), and types and subtypes of myopia of various etiologies and causes, either known or unknown, including, but not limited to, simple myopia, degenerative myopia, and form deprivation myopia.
  • the term “diopter” as used herein includes measurement of how much a corrective lens must bend light to focus the light on the retina to normalize the vision.
  • a lens that can bend parallel light rays to a focal point of 1 meter is said to have a power of 1 diopter (1.00 D).
  • a 2-diopters lens can focus light rays at a point 0.5 meters away from itself.
  • subject typically refers to a human or an animal subjected to the methods described herein. It is to be understood that a subject can be a patient with known or suspected myopia disorder, but subjects without known or suspected myopia disorder, such as research subjects, are also included within the scope of the term “subject.”
  • compositions for treating myopia, reducing ocular chondrogenic protein, reducing scleral chondrogenesis or reducing inflammation induced chondrogenesis are provided herein.
  • the pharmaceutical compositions comprising a combination of two anti-chondrogenesis agents preferably by advantageous synergistic effects of the combinations.
  • An anti-chondrogenesis agent is any agent which reduces or slows the process of chondrogenesis.
  • an anti-chondrogenesis agent in the pharmaceutical composition is a NSAID.
  • an anti-chondrogenesis agent in the pharmaceutical composition is an anti-muscarinic agent.
  • Non limiting examples of anti-chondrogenesis agent include a microRNA that regulates the expression of lymphoid enhancer-binding factor-1, such as miR-449a (S Paik, et al., miR-449a regulates the chondrogenesis of human mesenchymal stem cells through direct targeting of lymphoid enhancer-binding factor-1, Stem Cells Dev; 21(18):3298-308, 2012), a histone deacetylase inhibitor such as valproic acid (F H Paradis et al., Exposure to valproic acid inhibits chondrogenesis and osteogenesis in mid-organogenesis mouse limbs, Toxicol Sci; 131(1):234-41, 2013), Nicotine (Y Deng et al., Nicotine-induced retardation of chondrogenesis through down-regulation of IGF-1 signaling pathway to inhibit matrix synthesis of growth plate chondrocytes in fetal rats, Toxicol Appl Pharmacol; 269(1):25-33, 2013), b
  • the pharmaceutical composition includes at least one NSAID and at least one anti-muscarinic agent.
  • NSAIDs for use in the present invention may be non-selective cyclooxygenase (COX) inhibitors, its derivatives, salts and structural analogues, i.e., compounds that inhibit both COX-1 and COX-2 proteins.
  • COX non-selective cyclooxygenase
  • Non limiting examples of non-selective COX inhibitors include salicylic acid derivatives (e.g., aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, sulfasalazine and olsalazine), indole and indene acetic acids (e.g., indomethacin and sulindac), heteroaryl acetic acids (e.g., tolmetin, diclofenac and ketorolac), arylpropionic acids (e.g., ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, and oxaprozin), anthranilic acids (fenamates) (e.g., mefenamic acid and meclosfenamic acid), enolic acids (e.g., the oxicams, piroxicam and meloxicam) and alkanones
  • NSAIDs for use in the present invention may be selective COX-2 inhibitors, its derivatives, salts and structural analogues.
  • selective COX-of selective COX-2 inhibitor include diaryl-substituted furanones (e.g., rofecoxib), diaryl-substituted pyrazoles (e.g., celecoxib), indole acetic acids (e.g., etodolac) and sulfonanilides (e.g., nimesulide).
  • selective COX-2 inhibitor are disclosed in U.S. Pat. No. 6,440,963 and WO 2004/054560, which are incorporated by reference in its entirety.
  • Preferred NSAIDs for use in the invention include, but are not limited to, Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac and Flurbiprofen.
  • anti-muscarinic agent examples include, but are not limited to, Atropine, Homatropine, Scopolamine, its derivatives, salts, and structural analogues.
  • Anti-muscarinic agents may cause side effects of blurred vision and photophobia. These side effects maybe overcome by administering lower dosage of anti-muscarinic agents, in combination with one or more anti-chondrogenesis agent, to achieve the desired therapeutic effect.
  • the observed synergistic effect of a pharmaceutical composition comprising a combination of an anti-muscarinic agent (e.g. atropine) and an NSAID (e.g. ketorolac) may afford effective treatment of myopia wherein one or even all of the lower dosages of the anti-chondrogenesis agents would not be sufficient to have a therapeutic effect when the respective anti-chondrogenesis agent is used in monotherapy.
  • an anti-muscarinic agent e.g. atropine
  • an NSAID e.g. ketorolac
  • compositions to be administered according to the methods of some embodiments provided herein can be readily formulated with, prepared with, or administered with, a pharmaceutically acceptable carrier.
  • preparations may be prepared by various techniques. Such techniques include bringing into association active components (such as NSAID or anti-muscarinic agent) of the pharmaceutical compositions and an appropriate carrier.
  • pharmaceutical compositions are prepared by bringing into association active components of the pharmaceutical compositions with liquid carriers, with solid carriers, or with both.
  • compositions are administered in an aqueous suspension, an oil emulsion, water in oil emulsion and water-in-oil-in-water emulsion, and in carriers including, but not limited to, creams, gels, liposomes (neutral, anionic or cationic), lipid nanospheres or microspheres, neutral, anionic or cationic polymeric nanoparticles or microparticles, site-specific emulsions, long-residence emulsions, sticky-emulsions, micro-emulsions, nano-emulsions, microspheres, nanospheres, nanoparticles and minipumps, and with various natural or synthetic polymers that allow for sustained release of the pharmaceutical composition including anionic, neutral or cationic polysaccharides and anionic, neutral cationic polymers or copolymers, the minipumps or polymers being implanted in the vicinity of where composition delivery is required.
  • carriers including, but not limited to, creams, gels, liposomes (neutral, ani
  • compositions provided herein may optionally include anti-oxidants, buffers, bacteriostatic agents, suspending agents thickening agents, preservatives, co-solvents and viscosity building agents or other therapeutic ingredients.
  • the carrier and other therapeutic ingredients must be acceptable in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
  • Suitable preservatives for ophthalmic preparations include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M, or other agents known to those skilled in the art.
  • the preservative is employed at a level of from 0.004% to 0.02%.
  • active components of the pharmaceutical compositions provided herein are emulsified with a mineral oil or with a neutral oil such as, but not limited to, a diglyceride, a triglyceride, a phospholipid, a lipid, an oil and mixtures thereof, wherein the oil contains an appropriate mix of polyunsaturated and saturated fatty acids.
  • a neutral oil such as, but not limited to, a diglyceride, a triglyceride, a phospholipid, a lipid, an oil and mixtures thereof, wherein the oil contains an appropriate mix of polyunsaturated and saturated fatty acids.
  • examples include, but are not limited to, soybean oil, canola oil, palm oil, olive oil and myglyol, wherein the number of fatty acid carbons is between 12 and 22 and wherein the fatty acids can be saturated or unsaturated.
  • charged lipid or phospholipid is suspended in the neutral oil.
  • a suitable phospholipid is, but is not limited to, phosphatidy
  • the pharmaceutical compositions are administered in an amount effective to reduce ocular chondrogenic protein, reduce scleral chondrogenesis, reduce inflammation induced chondrogenesis or to induce a therapeutic response in an animal, including a human with myopia.
  • the dosage of the pharmaceutical composition administered will depend on the severity of the condition being treated, the particular formulation, and other clinical factors such as weight and the general condition of the recipient and route of administration.
  • the amount of the pharmaceutical composition administered corresponds to about 0.001% to about 1% by weight atropine.
  • the amount of the pharmaceutical composition administered corresponds to about 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.035%, 0.04%, 0.045%, 0.05%, 0.055%, 0.06%, 0.065%, 0.07%, 0.075%, 0.08%, 0.085%, 0.09%, 0.095%, 0.1% by weight atropine, or any % in between 0.001% and 1% in 0.001% increments.
  • the amount of the pharmaceutical composition administered corresponds to about 0.05% to about 1% by weight Ketorolac.
  • the amount of the pharmaceutical composition administered corresponds to about 0.1%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95% by weight Ketorolac, or any % in between in 0.01% increments. In another exemplary embodiment, the amount of the pharmaceutical composition administered corresponds to about 0.5% by weight Ketorolac. In another exemplary embodiment, the amount of the pharmaceutical composition administered corresponds to from about 0.01%, 0.025%, 0.05%, 0.1%, 0.15% to about 0.2% of Diclofenac by weight or any % in between in 0.01% increments.
  • Useful dosages of the pharmaceutical compositions provided herein are determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known in the art; for example, see U.S. Pat. No. 4,938,949, which is incorporated by reference herein.
  • the pharmaceutical composition is delivered by any of a variety of routes including, but not limited to, injection (e.g., subcutaneous, intramuscular, intravenous, intra-arterial, intraperitoneal, intradermal, intravitreal); cutaneously; dermally; transdermal; oral (e.g., tablet, pill, liquid medicine, edible film strip); implanted osmotic pumps; suppository, aerosol spray, topical, intra-articular, ocular, nasal inhalation, pulmonary inhalation, impression into skin and electroporation.
  • the pharmaceutical composition of the present invention can be administered as solution in a suitable ophthalmic vehicle.
  • the combination comprises 0.001% to about 0.005% by weight atropine and 0.1% to about 0.5% by weight Ketorolac solution in water at pH of 4.5 to 8.0, e.g. about 6.9. It is recommended that the solution be topically applied by placing one drop in the affected eye once a day.
  • the pharmaceutical composition may be administered in a single dose treatment or in multiple dose treatments, over a period of time appropriate to the condition being treated.
  • the pharmaceutical composition may conveniently be administered at appropriate intervals, for example, once a day, twice a day, three times a day, once every second day, once every three days or once every week, over a period of at least 3 months, at least 1 year, or until the symptoms and signs of myopia resolved.
  • the use of an effective amount of one or more anti-chondrogenesis agents or a pharmaceutical composition described herein may alter or reduce the amount of one or more ocular chondrogenic proteins in a subject in need thereof.
  • TGF- ⁇ ocular chondrogenic protein
  • the TGF- ⁇ protein is selected from the group consisting of TGF- ⁇ 1, TGF- ⁇ 2 and TGF- ⁇ 3, all of which are located predominately in the choroid.
  • TGF- ⁇ 1 TGF- ⁇ 2
  • TGF- ⁇ 3 TGF- ⁇ 3
  • ⁇ -SMA ocular chondrogenic protein
  • Col2 ocular chondrogenic protein
  • the present invention provides the use of an effective amount of one or more anti-chondrogenesis agents or a pharmaceutical composition described herein for reducing inflammation induced chondrogenesis in a subject in need thereof.
  • the inflammation markers responsible for inducing scleral chondrogenesis include, but are not limited to, IL-6 and TNF- ⁇ .
  • the present invention provides the use of an effective amount of one or more anti-chondrogenesis agents or a pharmaceutical composition described herein for reducing scleral chondrogenesis in a subject in need thereof.
  • the anti-chondrogenesis agent maybe administered concomitantly or non-concomitantly.
  • FIG. 1 illustrates a mechanism for the development of myopia, wherein increase levels of TGF- ⁇ s and inflammatory markers (such as IL-6 and TNF- ⁇ ) in the choroid lead to the formation of ⁇ -SMA and Col2 in the sclera and scleral chondrogenesis. The sclera then undergo remodeling and elongation, followed by the development of myopia.
  • TGF- ⁇ s and inflammatory markers such as IL-6 and TNF- ⁇
  • the present invention provides methods for treating or reducing the severity of myopia, by administering one or more anti-chondrogenesis agents in an effective amount or the pharmaceutical composition described herein to a myopic subject in need of myopia treatment.
  • the anti-chondrogenesis agent may be administered concomitantly or non-concomitantly.
  • the methods also encompass research methods and uses, including in vitro and in vivo methods of treating, or inhibiting the progression of myopia in the subject.
  • the method for treating myopia comprises identifying a myopic subject who exhibits side effect to anti-muscarinic agent, and treating said subject with an effective amount of NSAID, without the anti-muscarinic agent or with a lower dose of anti-muscarinic agent (e.g. 0.05% of atropine).
  • mice Male wild type C57BL/6 mice (Jackson Labs) were used in the examples. All procedures were performed in accordance with an institutional IACUC approved protocol as well as the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
  • SSPCs Scleral Stem/Progenitor Cells
  • the SSPCs were isolated and cultured as previously described by CL Tsai et al. (Identification of multipotent stem/progenitor cells in murine sclera. Invest Ophthalmol Vis Sci 52:5481-5487, 2011).
  • sclera from the mouse was obtained and was carefully dissected away from limbus and optic disc under a dissection microscope. After retina and choroid tissues were removed, the scleral tissue was cut into small pieces and digested with 1.5 mg/ml collagenase type I (Worthington Biochemical, Lakewood, USA) and 2 mg/ml of dispase (Roche, Basel, Switzerland) in PBS for 1 h at 37° C. to release individual cells.
  • TGF- ⁇ 2 Different concentrations of TGF- ⁇ 2 were added into 12-wells of SSPCs. After 24 hrs, the images of SSPC morphology were recorded. The total RNA was extracted for further analysis. A chamber slide culture for the immunofluorescence study was performed under the same condition.
  • SSPCs were trypsinized and counted to make aliquots of 2 ⁇ 10 5 cells in 2 ml growth medium which were spun down at 500 g for 10 min to obtain the pellet.
  • the pellets were incubated at 37° C., under 5% CO2. Within 12-24 h of incubation, the cells formed an essentially spherical aggregate that did not adhere to the walls of the tube.
  • Culture medium was added with 10 ng/ml TGF- ⁇ 2 and the medium was changed at 2 to 3 day intervals. The pellets were then harvested at 4 weeks. Subsequently, they were washed twice in PBS, fixed in 4% paraformaldehyde for 3 h at room temperature and prepared for paraffin embedment. Eight ⁇ m thick sections were obtained for immunohistochemistry,
  • Immunohistochemistry and immunofluorescence studies were performed to demonstrate the presence of ⁇ -SMA protein and Col2 during chondrogenesis.
  • paraffin sections were treated with a 20% blocking goat serum for 30 min, then incubated with primary antibodies which were rabbit IgG anti-SMA mAb at 1:200 dilution (Abcam, Temecula, Calif.) and mouse IgG2a anti-type II collagen mAbb at 1:100 dilution (Abcam, Temecula, Calif.) at 4° C. overnight.
  • the sections were then treated with horseradish peroxidase (HRP)-conjugated secondary antibodies at 1:200 (Santa Cruz Biotechnology, Santa Cruz, Calif.) for 1 hour.
  • HRP horseradish peroxidase
  • the DAB reagent (diaminobenzidine tetrahydrochloride) was subsequently used to detect the immunoactivity.
  • DAB reagent diaminobenzidine tetrahydrochloride
  • cryostat sections and rehydrated paraffin sections were treated with blocking serum, incubated with primary antibody, reacted with the corresponding fluorescein-isothiocyanate-conjugated secondary antibody, and finally evaluated by fluorescence microscopy.
  • RNA from SSPCs or the choroid tissue in each eye was isolated using Trizol (Invitrogen, Carlsbad, Calif.) accordingly to the manufacture's protocol.
  • qRT-PCR analysis was carried out using the iScript one-step RT-PCR kit with SYBR Green (Bio-Rad, Hercules, USA) on an ABI PRISM 7900 HT sequence detection system (Applied Biosystems, Foster City, USA), according to the manufacturer's instructions.
  • ⁇ -SMA Forward primer: 5′-ATGCCTCTGGACGTACAACTG-3′, Reverse primer: 5′-CGGCAGTAGTCACGAAGGAAT-3′
  • Col2 Forward primer: 5′-GTCCTTCTGGCCCTAGAGGT-3′, Reverse primer: 5′-TGTTTCTCCTGAGCGTCCA-3′
  • ⁇ -actin Formward primer: 5′-CATTGCTGACAGGATGCAGA-3′, Reverse primer: 5′-CTGATCCACATCTGCTGGAA-3′
  • GAPDH glyceraldehyde 3-phosphate dehydrogenase
  • GAPDH and ⁇ -actin served as controls. Ct values of the control gene were subtracted from those of ⁇ -SMA and Col2 to provide a semiquantitative analysis, and fold change
  • mice were anesthetized by intraperitoneal injection of ketamine (90 mg/kg) and xylazine (10 mg/kg), and the diffuser eye patches were sutured to the skin around the right eye whereas the left eye served as a control.
  • the hemispherical plastic diffuser eye patches were made from caps of 0.5-mL PCR plastic tubes. The mice were recovered and monitored on a warming pad until they were fully mobile. Deprived myopia mice were housed in transparent plastic cages under 12 hours of light (200 ⁇ 15 lux horizontal illuminance) and 12 hours of darkness for 21 days.
  • a spectral-domain optical coherence tomography was used for ocular biometric measurement before and after form-deprived myopia induction.
  • the total protein from the sclera was extract by using RIPA protein extraction buffer. After homogenization of scleral tissue, the sample was centrifuged and the supernatant was collected. The protein concentration of each sample was measured using a BCATM protein Assay Kit (Bio-Rad). Scleral protein samples were standardized and electrophoresed on 10% SDS-PAGE gel, then transferred to a polyvinylidene fluoride transfer membrane (Immun-Blot PVDF Membrane, BIO-RAD) at 21 V for 1 h. Membranes were blocked for 1 h at room temperature with 5% dry milk in PBS with 0.1% Tween and incubated at 4° C. overnight with primary antibodies.
  • Membranes were washed and incubated with 1:10,000 goat anti-mouse or anti-rabbit IgG antibodies conjugated to horseradish peroxidase (Santa Cruz) for 1 h at room temperature and washed again. Membranes were developed by chemiluminescence with the reagent Lumigen TMA-6 (GE Healthcare UK limited, Buckinghumshire, UK) and images were captured with the LAS-4000 imaging system (Fujifilm, Tokyo, Japan). Protein bands were quantified using ImageJ software.
  • SSPC pellets were cultured in control medium and medium containing 10 ng/ml of TGF- ⁇ 2 (TM-pellets) for 4 weeks. Histological analysis showed that most SSPC were located in the midperipheral and peripheral area which surrounded the central matrix tissue in TM-pellets. Immunohistochemical analysis showed Col2 was expressed in the local, mid-peripheral area of TM-pellets whereas ⁇ -SMA expression was more extensive within the TM-pellets, especially in mid-peripheral area and peripheral area. In contrast, Col2 and ⁇ -SMA expressions were less in the control group.
  • FIG. 3 shows after 21 days of visual deprivation, the expressions of Col2 and ⁇ -SMA were higher in the sclera of FDM eyes using western blot analysis.
  • Immunostaining shows Col2 expression was higher in the scleral region of the FDM eyes than in the control eyes, whereas ⁇ -SMA expression was greater in the scleral (close to the choroid side) and choroid areas of FDM eyes in comparison to control eyes.
  • FIGS. 5A and 5B show the expressions of Col2 and ⁇ -SMA were suppressed by atropine, ketorolac and diclofenac, in the presence of TGF- ⁇ 2.
  • 11 myopic patients received atropine treatment for at least a year, with the dose of atropine ranged from 0.005% to 1% weight atropine per unit dose (about 0.05 to 0.5 ml). Each affected eye was given one drop (about 0.05 to 0.5 ml) of atropine ophthalmic solution at night. During the atropine treatment, the average myopia progression rate for these 11 myopic patients was ⁇ 0.9 Diopter/year.
  • these 11 myopic patients received a pharmaceutical composition comprising atropine and ketorolac for at least 3 months.
  • the dose of atropine ranged from about 0.005% to about 1% weight atropine per unit dose (about 0.05 to 0.5 ml) and the dose of ketorolac ranged from about 0.25% to about 0.5% weight ketorolac per unit dose (0.5 ml).
  • Each affected eye was given one drop (about 0.05 to 0.5 ml) of combined atropine with ketorolac ophthalmic solution at night.
  • the average myopia progression rate for these 11 myopia patients reduced to ⁇ 0.38 Diopter/year ( FIG. 6 ).
  • ketorolac A myopic patient could not tolerate the side effects of atropine and was given NSAID to treat his myopia.
  • the dose of ketorolac was about 0.5% weight ketorolac per unit dose (about 0.05 to 0.5 ml) and the affected eye was given one drop (about 0.05 to 0.5 ml) of ketorolac ophthalmic solution at night.
  • the average myopia progression rate for this patient was ⁇ 0.78 Dioptor per year in right eye and ⁇ 0.91 Diopter per year in left eye without any treatment. After three months of NSAID treatment, there was no myopia progression in both eyes ( FIG. 7 ).
  • FIG. 8A shows the level of IL-6 by real-time PCR in the choroids of FDM eye was higher than that of control eye.
  • FIG. 8 b shows the level of TNF- ⁇ by real-time PCR in the choroids of FDM eye was higher than that of control eye.
  • the level of TNF- ⁇ was suppressed by administering one ketorolac eye drop once a day to the FDM eye.
  • FIG. 9A shows the expression of ⁇ -SMA increased in the presence of TGF- ⁇ 2 (T2) but reduced with 0.5 mM of atropine (A), 0.25 mM of Ketorolac (X1), and a pharmaceutical composition comprising Atropine and Ketorolac, in the presence of TGF- ⁇ 2.
  • FIG. 9B shows the expression of Col2 increased in the presence of TGF- ⁇ 2 (T2) but reduced with 0.5 mM of atropine (A), 0.25 mM of Ketorolac (X1), and a pharmaceutical composition comprising Atropine and Ketorolac, in the presence of TGF- ⁇ 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US14/787,051 2013-05-06 2014-05-05 Pharmaceutical composition and uses thereof Abandoned US20160067238A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/787,051 US20160067238A1 (en) 2013-05-06 2014-05-05 Pharmaceutical composition and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819709P 2013-05-06 2013-05-06
PCT/US2014/036810 WO2014182620A1 (fr) 2013-05-06 2014-05-05 Composition pharmaceutique et utilisations de celle-ci
US14/787,051 US20160067238A1 (en) 2013-05-06 2014-05-05 Pharmaceutical composition and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/036810 A-371-Of-International WO2014182620A1 (fr) 2013-05-06 2014-05-05 Composition pharmaceutique et utilisations de celle-ci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/958,440 Division US10548887B2 (en) 2013-05-06 2018-04-20 Pharmaceutical composition and uses thereof

Publications (1)

Publication Number Publication Date
US20160067238A1 true US20160067238A1 (en) 2016-03-10

Family

ID=51867665

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/787,051 Abandoned US20160067238A1 (en) 2013-05-06 2014-05-05 Pharmaceutical composition and uses thereof
US15/958,440 Active US10548887B2 (en) 2013-05-06 2018-04-20 Pharmaceutical composition and uses thereof
US16/701,707 Active US10888556B2 (en) 2013-05-06 2019-12-03 Method for treating myopia with an nsaid and an anti-muscarinic agent

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/958,440 Active US10548887B2 (en) 2013-05-06 2018-04-20 Pharmaceutical composition and uses thereof
US16/701,707 Active US10888556B2 (en) 2013-05-06 2019-12-03 Method for treating myopia with an nsaid and an anti-muscarinic agent

Country Status (11)

Country Link
US (3) US20160067238A1 (fr)
EP (1) EP2994197B1 (fr)
JP (2) JP6208332B2 (fr)
KR (2) KR102027663B1 (fr)
CN (1) CN105555363B (fr)
CA (2) CA2911298C (fr)
ES (1) ES2871116T3 (fr)
HK (1) HK1219691A1 (fr)
SG (1) SG11201508453YA (fr)
TW (2) TWI562776B (fr)
WO (1) WO2014182620A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018749A1 (fr) 2017-07-20 2019-01-24 Alan Laboratories, Inc. Composition et méthodes pour le traitement de la myopie
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
KR20200110369A (ko) 2018-01-17 2020-09-23 아이노비아 인코포레이티드 액적의 마이크로-용량 스트림으로 안구에 아트로핀을 전달하기 위한 방법 및 장치

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095913A1 (fr) * 2000-06-13 2001-12-20 Synphora Ab Procedes et compositions destines a la prevention de la myopie

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01226313A (ja) * 1988-03-07 1989-09-11 Toyota Motor Corp 樹脂成形品の製造方法
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
KR920002149A (ko) * 1990-07-03 1992-02-28 안드레아 엘. 콜비 비스테로이드계 소염제에 의해 유발된 위장 장애 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법
JP2000026313A (ja) * 1998-05-06 2000-01-25 Hokuriku Seiyaku Co Ltd 消化管運動抑制剤
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
CN101327325A (zh) * 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
CA2509605C (fr) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Ligand alpha-2-delta pour traiter des symptomes des voies urinaires inferieures
AU2005294382A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
CN1302812C (zh) 2004-11-30 2007-03-07 中国海洋大学 含海藻糖和玻璃酸的眼部用药传递系统及其制备方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
KR20100087291A (ko) 2007-09-25 2010-08-04 아보트 러보러터리즈 케모카인 수용체 길항제로서의 옥타하이드로펜탈렌 화합물
US20110054031A1 (en) * 2008-02-21 2011-03-03 Ista Pharmaceuticals, Inc. Ophthalmic NSAIDS as Adjuvants
US9046699B2 (en) 2012-03-13 2015-06-02 Johnson & Johnson Vision Care, Inc. Dynamic fluid zones in contact lenses
WO2013166408A1 (fr) * 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Nanoparticules pharmaceutiques présentant un transport muqueux amélioré
CN104394856A (zh) 2012-05-21 2015-03-04 Dcb美国公司 以斑马鱼模型进行药物筛选的方法及筛选所得药物
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095913A1 (fr) * 2000-06-13 2001-12-20 Synphora Ab Procedes et compositions destines a la prevention de la myopie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Solomon et al. (Ophthamology, 108, 2001, 331-337; abstract only) *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071732B2 (en) 2017-05-11 2021-07-27 Nevakar Inc. Atropine pharmaceutical compositions
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
US10568875B2 (en) 2017-05-11 2020-02-25 Nevakar Inc. Atropine pharmaceutical compositions
US10576074B2 (en) 2017-05-11 2020-03-03 Nevakar Inc. Atropine pharmaceutical compositions
US10583132B2 (en) 2017-05-11 2020-03-10 Nevakar Inc. Atropine Pharmaceutical Compositions
US10610525B2 (en) 2017-05-11 2020-04-07 Nevakar Inc. Atropine pharmaceutical compositions
US11464769B2 (en) 2017-05-11 2022-10-11 Vyluma Inc. Atropine pharmaceutical compositions
US11642338B2 (en) 2017-05-11 2023-05-09 Vyluma Inc. Atropine pharmaceutical compositions
US11707458B2 (en) 2017-05-11 2023-07-25 Vyluma Inc. Atropine pharmaceutical compositions
US11730728B2 (en) 2017-05-11 2023-08-22 Vyluma Inc. Atropine pharmaceutical compositions
US11730727B2 (en) 2017-05-11 2023-08-22 Vyluma Inc. Atropine pharmaceutical compositions
WO2019018749A1 (fr) 2017-07-20 2019-01-24 Alan Laboratories, Inc. Composition et méthodes pour le traitement de la myopie
US11285141B2 (en) 2017-07-20 2022-03-29 Seinda Pharmaceutical Guangzhou Corporation Composition and methods for the treatment of myopia

Also Published As

Publication number Publication date
US20180311227A1 (en) 2018-11-01
SG11201508453YA (en) 2015-11-27
TW201446245A (zh) 2014-12-16
EP2994197A1 (fr) 2016-03-16
CN105555363A (zh) 2016-05-04
TWI562776B (en) 2016-12-21
EP2994197A4 (fr) 2016-12-28
TWI617306B (zh) 2018-03-11
KR20170094552A (ko) 2017-08-18
ES2871116T3 (es) 2021-10-28
KR20160004288A (ko) 2016-01-12
CA3050457A1 (fr) 2014-11-13
TW201641105A (zh) 2016-12-01
KR102027663B1 (ko) 2019-10-01
JP2018008991A (ja) 2018-01-18
US10548887B2 (en) 2020-02-04
CA2911298C (fr) 2019-09-17
JP2016518410A (ja) 2016-06-23
JP6208332B2 (ja) 2017-10-04
US10888556B2 (en) 2021-01-12
US20200113890A1 (en) 2020-04-16
CA3050457C (fr) 2021-05-25
JP6450814B2 (ja) 2019-01-09
HK1219691A1 (zh) 2017-04-13
CN105555363B (zh) 2019-03-12
EP2994197B1 (fr) 2021-04-28
WO2014182620A1 (fr) 2014-11-13
CA2911298A1 (fr) 2014-11-13

Similar Documents

Publication Publication Date Title
US10888556B2 (en) Method for treating myopia with an nsaid and an anti-muscarinic agent
US11690812B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
CN106456662A (zh) 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
TWI532480B (zh) 以斑馬魚模組進行藥物篩選之方法及篩選所得藥物
Vitar et al. Modulating ocular surface pain through neurokinin-1 receptor blockade
Wang et al. HSP27 regulates TGF-β mediated lung fibroblast differentiation through the Smad3 and ERK pathways
JP2016530291A (ja) 脆弱ｘ症候群および関連障害の処置方法
Lei et al. Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway
Lan et al. Chronic exposure of alcohol triggers microglia-mediated synaptic elimination inducing cognitive impairment
TR201815345T4 (tr) Nörodejenertif hastalıkların tedavisinde kullanıma yönelik tauroursodeoksikolik asit (tudca).
Bitzer et al. Effects of muscarinic antagonists on ZENK expression in the chicken retina
EP3156064B1 (fr) Utilisation de protéine yb-1 ou de fragments de celle-ci afin de préparer des agents médicamenteux pour le traitement de la maladie d'alzheimer
US9987242B2 (en) Treatment of Levodopa-induced Dyskinesias
US20230000760A1 (en) Compositions and methods for treating ocular disorders
WO2022123837A1 (fr) Collyre pour le traitement de l'amincissement scléral et procédé de criblage pour agent thérapeutique d'amincissement scléral
Luo et al. Dexamethasone protects against arsanilic acid‑induced rat vestibular dysfunction through the BDNF and JNK 1/2 signaling pathways
Festa Mechanistic Insights & Therapeutic Approaches in Endolysosomal Disorders Affecting the Kidney Proximal Tubule
Khan Investigating the mechanisms of action of phytocannabinoids and a novel cognitive enhancer to target the comorbidity of temporal lobe epilepsy
Cabezas Llobet Therapeutic potential of pituitary adenylate cyclase-activating polypeptide and epigallocatechin gallate in motor and cognitive deficits of Huntington's disease models
EA045318B1 (ru) Соединения для лечения глазных болезней, связанных с избыточной васкуляризацией
Roggia Mechanisms of Senescence in Retinal Pigment Epithelial Cells
EP3148550A1 (fr) Traitement de la vitréorétinopathie exsudative familiale par inhibition de s1pr2

Legal Events

Date Code Title Description
AS Assignment

Owner name: WU, PHILIP, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, PEI-CHANG;TSAI, CHIA-LING;CHEN, CHUEH-TAN;SIGNING DATES FROM 20140501 TO 20160501;REEL/FRAME:039022/0272

Owner name: KAOHSIUNG CHANG GUNG MEMORIAL HOSPITAL, TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, PEI-CHANG;TSAI, CHIA-LING;CHEN, CHUEH-TAN;SIGNING DATES FROM 20140501 TO 20160501;REEL/FRAME:039022/0272

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION